Bevacizumab and Lomustine for Recurrent GBM
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01290939 |
Recruitment Status :
Completed
First Posted : February 7, 2011
Last Update Posted : February 15, 2021
|
Sponsor:
European Organisation for Research and Treatment of Cancer - EORTC
Collaborator:
Hoffmann-La Roche
Information provided by (Responsible Party):
European Organisation for Research and Treatment of Cancer - EORTC
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Completed |
---|---|
Actual Primary Completion Date : | October 2015 |
Actual Study Completion Date : | April 2020 |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):